Shwetha Lakshmipathi

Shwetha Lakshmipathi has a diverse work experience in the field of biotherapeutics and immunology. Shwetha is currently working as an Associate Director of Process Science and Engineering at Instil Bio since September 2021. Prior to this, they worked as a Process Development Scientist at Iovance Biotherapeutics, Inc. from January 2019 to September 2021, where they played a key role in process development and optimization of manufacturing processes for clinical protocols and IND submissions.

Shwetha has also worked as a PhD Student at Technische Universität München from April 2013 to January 2018, where they conducted research in the field of immunology. Shwetha has experience as a Research Associate II/Post Doctoral candidate at Moffitt Cancer Center from February 2017 to July 2017, focusing on adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) and performing immunological assays.

In addition, Shwetha worked as a Postgraduate Research Student at the University of Cologne from January 2012 to May 2012 and as a Postgraduate Student at the University of Nottingham from September 2010 to December 2011. At the University of Nottingham, they conducted research on biomarkers in colorectal cancer using immunohistochemistry and tissue microarray under the supervision of Prof. Lindy Durrant.

Shwetha started their career as a Clinical Data Reviewer at GSK Pharmaceuticals India in October 2007 and worked there until August 2010. In this role, they reviewed and generated documents for scientific writing for various vaccine projects, including HPV, Malaria, and Rotavirus.

Overall, Shwetha Lakshmipathi has extensive experience in process development, immunology research, and clinical data review in the biopharmaceutical industry.

Shwetha Lakshmipathi's education history begins with their Bachelor of Engineering degree in Biotechnology from Visvesvaraya Technological University, which they completed from 2003 to 2007. Shwetha then pursued a Master of Science degree in Cancer immunology and biotechnology from the University of Nottingham, which they obtained from 2010 to 2011.

Afterwards, they enrolled at the Technical University of Munich, where they completed their first Doctor of Philosophy (PhD) in Medical Life Science Technology from 2013 to 2018. Their research focused on the field of Medical Life Science Technology.

In addition, it is mentioned that they pursued a second Doctor of Philosophy (PhD) in Cell and Gene therapy within the same field of Medical Life Science Technology at the Technical University of Munich, although the specific start and end years for this degree are not provided.

Lastly, there is a mention of the "Univers" without further details regarding degree or field of study, so no assumptions can be made about this particular aspect of their education history.